relief medicine Buscopan (hyoscine butylbromide), among others. Sales in the business totalled €5.6bn ($5.8bn) in 2023, accounting for 11% of Sanofi’s total business. Sanofi also claims Opella ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), emphasized increased funding in ... to show the scale of the company's drug contributions to the industry. Sanofi (NASDAQ:SNY) is a ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Emanuele de Rinaldis, global head of precision medicine and computational biology at Sanofi, commented: “[O]ur drug discovery strategy is driven by precision medicine. We seek to describe ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted ... If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid (BP) in the ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...